Cuesta-Mateos Carlos, Terrón Fernando, Herling Marco
Immunology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria- Instituto la Princesa (IIS-IP), Madrid, Spain.
Immunological and Medicinal Products (IMMED S.L.), Madrid, Spain.
Front Oncol. 2021 Oct 29;11:736758. doi: 10.3389/fonc.2021.736758. eCollection 2021.
According to the classical paradigm, CCR7 is a homing chemokine receptor that grants normal lymphocytes access to secondary lymphoid tissues such as lymph nodes or spleen. As such, in most lymphoproliferative disorders, CCR7 expression correlates with nodal or spleen involvement. Nonetheless, recent evidence suggests that CCR7 is more than a facilitator of lymphatic spread of tumor cells. Here, we review published data to catalogue CCR7 expression across blood cancers and appraise which classical and novel roles are attributed to this receptor in the pathogenesis of specific hematologic neoplasms. We outline why novel therapeutic strategies targeting CCR7 might provide clinical benefits to patients with CCR7-positive hematopoietic tumors.
根据经典范式,CCR7是一种归巢趋化因子受体,可使正常淋巴细胞进入二级淋巴组织,如淋巴结或脾脏。因此,在大多数淋巴增殖性疾病中,CCR7的表达与淋巴结或脾脏受累相关。尽管如此,最近的证据表明,CCR7不仅仅是肿瘤细胞淋巴扩散的促进因子。在这里,我们回顾已发表的数据,以梳理各种血液癌症中CCR7的表达情况,并评估该受体在特定血液系统肿瘤发病机制中所具有的经典和新作用。我们概述了为何针对CCR7的新型治疗策略可能会给CCR7阳性造血肿瘤患者带来临床益处。